Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Alexion Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00844545
First received: February 13, 2009
Last updated: June 11, 2014
Last verified: June 2014

February 13, 2009
June 11, 2014
May 2009
July 2013   (final data collection date for primary outcome measure)
Assess the effect of eculizumab to reduce thrombotic microangiopathy (TMA). [ Time Frame: Through 26 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00844545 on ClinicalTrials.gov Archive Site
  • Additional efficacy endpoints related to manifestations of TMA. [ Time Frame: Through 26 weeks ] [ Designated as safety issue: No ]
  • Pharmacokinetics (PK) and pharmacodynamics (PD) of eculizumab in patients with aHUS. [ Time Frame: Through 26 weeks ] [ Designated as safety issue: Yes ]
  • Overall safety and tolerability of eculizumab. [ Time Frame: Through 26 weeks ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS
An Open-Label, Multi-Center Controlled Clinical Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant Atypical Hemolytic Uremic Syndrome (aHUS)

The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of adult patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS).

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Atypical Hemolytic Uremic Syndrome
Drug: Eculizumab
Intravenously administered 900mg once per week for 4 weeks, 1200 mg on week 5 then 1200mg every 2 weeks thereafter.
Experimental: eculizumab
Intervention: Drug: Eculizumab
Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013 Jun 6;368(23):2169-81. doi: 10.1056/NEJMoa1208981.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
16
July 2013
July 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male or female patients ≥18 years of age who have been diagnosed with Atypical Hemolytic-Uremic Syndrome (aHUS).
  2. Decrease in platelet count despite at least 4 plasma therapy (PT) treatments in the 1 week immediately prior to screening.

    1. Screening platelet count , 150 x109/L and at least 25% lower than remission platelet count or
    2. If remission counts not available, screening platelet count <75x109/L
  3. Diagnosis of aHUS
  4. Lactate dehydrogenase (LDH) level ≥ ULN.
  5. Creatinine level ≥ ULN for age.
  6. Sexually active women of childbearing potential must be practicing an effective, reliable and medically acceptable contraceptive regimen during the entire duration of the study, including the follow-up period.
  7. Able to give written informed consent.
  8. Able and willing to comply with study procedures.

Exclusion Criteria:

  1. ADAMTS-13 inhibitor or deficiency (i.e., ADAMTS-13 activity <5%) as measured at the screening visit.
  2. Malignancy.
  3. Typical HUS (Shiga toxin +).
  4. Known HIV infection.
  5. Identified drug exposure-related HUS.
  6. Infection-related HUS.
  7. Renal function status requiring chronic dialysis
  8. Presence or suspicion of active and untreated systemic bacterial infection that, in the opinion of the Investigator confounds an accurate diagnosis of aHUS or impedes the ability to manage the aHUS disease.
  9. Pregnancy or lactation.
  10. Unresolved meningococcal disease.
  11. Known Systemic Lupus Erythematosus (SLE) or antiphospholipid antibody positivity or syndrome.
  12. Any medical or psychological condition that, in the opinion of the investigator, could increase the patient's risk by participating in the study or confound the outcome of the study.
  13. Patients receiving IVIg or Rituximab therapy.
  14. Patients receiving other immunosuppressive therapies such as steroids, mTOR inhibitors or FK506 inhibitors are excluded unless: [1] part of a post-transplant anti-rejection regime, [2] patient has confirmed anti-CFH antibody requiring immunosuppressive therapy and [3] dose of such medications have been unchanged for at least 4 weeks prior to the screening period.
  15. Patients receiving Erythrocyte Stimulating Agents (ESAs) unless already on a stable dose for at least 4 weeks prior to the screening period.
  16. Participation in any other investigational drug trial or exposure to other investigational agent, device, or procedures beginning 4 weeks prior to screening and throughout the entire trial.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
France,   United States,   United Kingdom,   Austria
 
NCT00844545
C08-002A, BB-IND-11075, EudraCT Number 2008-006952-23
Yes
Alexion Pharmaceuticals
Alexion Pharmaceuticals
Not Provided
Not Provided
Alexion Pharmaceuticals
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP